Sign in
ALGS Stock Price, Chart, Stats & News
Aligos Therapeutics, Inc.
Save
34.04M
Market cap
–
Current P/E
–
Forward P/E
ALGS chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 76.40% |
Operating margin | -4024.93% |
Pretax margin | -1092.36% |
Net margin | -1106.72% |
Effective tax rate | -1.31% |
ROA | -27.01% |
ROE | -28.16% |
D/E | 0.10x |
Interest coverage ratio | – |
ALGS valuation
P/E | – |
P/S | 18.85x |
P/B | 1.29x |
P/CF | -0.84x |
P/FCF | -0.50x |
P/OCF | -0.84x |
PEG | -0.03x |
EV multiple | -0.63x |
About
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials.
Similar securities
Based on sector and market capitalization
Report issue